8-K: Carisma Therapeutics Faces Imminent Nasdaq Delisting, Pursues Reverse Stock Split and Merger to Maintain Listing

Carisma Therapeutics Inc. received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement and is planning a reverse stock split and a merger with OrthoCellix, Inc. to regain compliance.

Summary

• Carisma Therapeutics Inc. (CARM) was notified by Nasdaq on July 9, 2025, that its failure to regain compliance with the minimum bid price rule could serve as an additional basis for delisting.
• The company did not timely regain compliance with the Nasdaq Global Market (NGM) Bid Price Rule ($1.00 minimum) by the July 7, 2025, deadline, following an initial notification on January 6, 2025.
• Carisma's listing was transferred to The Nasdaq Capital Market (NCM) effective June 12, 2025, after a Nasdaq Hearings Panel decision on June 10, 2025, granted an exception until October 7, 2025, to comply with NCM listing criteria, including the bid price rule.
• A special meeting of stockholders is scheduled for August 5, 2025, to approve an amendment to the certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-10 and not greater than 1-for-50 shares.
• The primary purpose of the reverse stock split is to increase the per-share closing bid price to meet the NCM Bid Price Rule and help ensure continued Nasdaq listing.
• The proposed reverse stock split is also in connection with a proposed merger involving Carisma and OrthoCellix, Inc.

Sentiment

Score: 2

Explanation: The document indicates severe ongoing compliance issues with Nasdaq, including failure to meet bid price requirements and market value rules, leading to a delisting threat. While a plan (reverse stock split and merger) is in place, there is explicit uncertainty regarding its success in preventing delisting. This suggests a highly negative outlook for the company's immediate future and stock value.

Positives

• Nasdaq granted a transfer of listing to The Nasdaq Capital Market (NCM) with an exception period until October 7, 2025, to regain compliance.
• The company has a defined plan to address the bid price deficiency through a proposed reverse stock split and is pursuing a strategic merger.

Negatives

• Carisma Therapeutics Inc. failed to regain compliance with Nasdaq's minimum bid price rule by the July 7, 2025, deadline.
• The non-compliance could serve as an additional basis for delisting from Nasdaq.
• The company was previously notified of non-compliance with market value of publicly held shares and market value of listed securities requirements.

Risks

• There is no assurance that the proposed reverse stock split, if effected, will enable the company to demonstrate compliance with the Nasdaq Capital Market (NCM) Bid Price Rule.
• There is no assurance that the company will be able to satisfy the terms of the Nasdaq Hearings Panel's decision by October 7, 2025.
• There is no assurance that the company will achieve Nasdaq compliance standards and other Nasdaq requirements and conditions for listing.

Future Outlook

The company plans to hold a special meeting on August 5, 2025, to approve a reverse stock split at a ratio of 1-for-10 to 1-for-50 shares, aiming to increase its per-share bid price and regain Nasdaq compliance by the October 7, 2025, deadline. This action is also in connection with a proposed merger with OrthoCellix, Inc. However, there is no assurance that these actions will successfully prevent delisting.

Management Comments

• "The primary purpose for the reverse stock split is to increase the per-share closing bid price of the Company's common stock so as to demonstrate compliance with the applicable NCM Bid Price Rule, and to help ensure the Company's continued listing on Nasdaq."

Industry Context

This situation reflects the challenges faced by smaller biotechnology or pharmaceutical companies, often pre-revenue or early-stage, in maintaining Nasdaq listing requirements, particularly the minimum bid price. Such companies frequently rely on capital markets for funding, and continued listing is crucial for investor confidence and liquidity. Reverse stock splits are a common, though often last-resort, measure to avoid delisting, but do not address underlying business fundamentals. The proposed merger suggests a strategic move to potentially combine resources or pipeline assets, which is also common in the biotech sector for survival or growth.

Comparison to Industry Standards

• Many small-cap biotechnology companies, especially those in clinical development stages without significant revenue, frequently face challenges in maintaining Nasdaq's minimum bid price requirement. For example, companies like Athersys, Inc. (ATHX) or Sorrento Therapeutics, Inc. (SRNEQ) have faced similar delisting threats and resorted to reverse stock splits or sought alternative listing venues.
• The 1-for-10 to 1-for-50 reverse stock split ratio is within the typical range seen for companies attempting to cure bid price deficiencies, similar to splits enacted by companies such as Sesen Bio, Inc. (SESN, now Carisma Therapeutics Inc. itself after a merger) or other micro-cap biotechs.
• The transfer from Nasdaq Global Market to Nasdaq Capital Market is a common step for companies struggling with listing requirements, as NCM has slightly less stringent criteria, offering a temporary reprieve.

Corporate Governance

Stakeholder Impact

• Shareholders face potential delisting risk, significant dilution from reverse stock split (though not in terms of percentage ownership, but per-share value perception), and uncertainty regarding the company's future listing status and the success of the proposed merger. Voting on the reverse stock split is a key decision point.
• Employees may experience uncertainty regarding the company's long-term viability and strategic direction, especially with ongoing compliance issues and a proposed merger.
• Customers and partners may experience potential impact on confidence and future collaborations due to the company's precarious listing status.

Next Steps

• Hold a special meeting of stockholders on August 5, 2025, to approve a reverse stock split.
• Effect a reverse stock split at a ratio of not less than 1-for-10 and not greater than 1-for-50 shares, if approved.
• Work to satisfy the terms of the Nasdaq Hearings Panel's decision by October 7, 2025, to maintain NCM listing.
• File relevant materials with the SEC, including a registration statement on Form S-4, in connection with the proposed merger with OrthoCellix, Inc.

Key Dates

Recommendation

Keywords

Carisma Therapeutics, CARM, Nasdaq, Delisting, Reverse Stock Split, Minimum Bid Price, Nasdaq Capital Market, OrthoCellix, Merger, SEC Filing, 8-K, Compliance, Biotechnology, Pharmaceutical